RATIONALE: Surfactant protein (SP)-D and SP-A have been implicated in immunomodulation in the lung. It has been reported that patients with idiopathic pulmonary fibrosis (IPF) often have elevated serum levels of SP-A and SP-D, although their role in the disease is not known. OBJECTIVES: The goal of this study was to test the hypothesis that SP-D plays an important role in lung fibrosis using a mouse model of fibrosis induced by bleomycin (BLM). METHODS: Triple transgenic inducible SP-D mice (iSP-D mice), in which rat SP-D is expressed in response to doxycycline (Dox) treatment, were administered BLM (100 U/kg) or saline subcutaneously using miniosmotic pumps. MEASUREMENTS AND MAIN RESULTS: BLM-treated iSP-D mice off Dox (SP-D off) had increased lung fibrosis compared with mice on Dox (SP-D on). SP-D deficiency also increased macrophage-dominant cell infiltration and the expression of profibrotic cytokines (transforming growth factor [TGF]-β1, platelet-derived growth factor-AA). Alveolar macrophages isolated from BLM-treated iSP-D mice off Dox (SP-D off) secreted more TGF-β1. Fibrocytes, which are bone marrow-derived mesenchymal progenitor cells, were increased to a greater extent in the lungs of the BLM-treated iSP-D mice off Dox (SP-D off). Fibrocytes isolated from BLM-treated iSP-D mice off Dox (SP-D off) expressed more of the profibrotic cytokine TGF-β1 and more CXCR4, a chemokine receptor that is important in fibrocyte migration into the lungs. Exogenous SP-D administered intratracheally attenuated BLM-induced lung fibrosis in SP-D(-/-) mice. CONCLUSIONS: These data suggest that alveolar SP-D regulates numbers of macrophages and fibrocytes in the lungs, profibrotic cytokine expression, and fibrotic lung remodeling in response to BLM injury.
RATIONALE: Surfactant protein (SP)-D and SP-A have been implicated in immunomodulation in the lung. It has been reported that patients with idiopathic pulmonary fibrosis (IPF) often have elevated serum levels of SP-A and SP-D, although their role in the disease is not known. OBJECTIVES: The goal of this study was to test the hypothesis that SP-D plays an important role in lung fibrosis using a mouse model of fibrosis induced by bleomycin (BLM). METHODS: Triple transgenic inducible SP-Dmice (iSP-D mice), in which ratSP-D is expressed in response to doxycycline (Dox) treatment, were administered BLM (100 U/kg) or saline subcutaneously using miniosmotic pumps. MEASUREMENTS AND MAIN RESULTS: BLM-treated iSP-D mice off Dox (SP-D off) had increased lung fibrosis compared with mice on Dox (SP-D on). SP-D deficiency also increased macrophage-dominant cell infiltration and the expression of profibrotic cytokines (transforming growth factor [TGF]-β1, platelet-derived growth factor-AA). Alveolar macrophages isolated from BLM-treated iSP-D mice off Dox (SP-D off) secreted more TGF-β1. Fibrocytes, which are bone marrow-derived mesenchymal progenitor cells, were increased to a greater extent in the lungs of the BLM-treated iSP-D mice off Dox (SP-D off). Fibrocytes isolated from BLM-treated iSP-D mice off Dox (SP-D off) expressed more of the profibrotic cytokine TGF-β1 and more CXCR4, a chemokine receptor that is important in fibrocyte migration into the lungs. Exogenous SP-D administered intratracheally attenuated BLM-induced lung fibrosis in SP-D(-/-) mice. CONCLUSIONS: These data suggest that alveolar SP-D regulates numbers of macrophages and fibrocytes in the lungs, profibrotic cytokine expression, and fibrotic lung remodeling in response to BLM injury.
Authors: Kevin K Kim; Matthias C Kugler; Paul J Wolters; Liliane Robillard; Michael G Galvez; Alexis N Brumwell; Dean Sheppard; Harold A Chapman Journal: Proc Natl Acad Sci U S A Date: 2006-08-21 Impact factor: 11.205
Authors: Jeffrey W Card; James W Voltz; Michelle A Carey; J Alyce Bradbury; Laura M Degraff; Fred B Lih; James C Bonner; Daniel L Morgan; Gordon P Flake; Darryl C Zeldin Journal: Am J Respir Cell Mol Biol Date: 2007-05-11 Impact factor: 6.914
Authors: Scarlett Geunes-Boyer; Timothy N Oliver; Guilhem Janbon; Jennifer K Lodge; Joseph Heitman; John R Perfect; Jo Rae Wright Journal: Infect Immun Date: 2009-05-18 Impact factor: 3.441
Authors: Antje Moeller; Sarah E Gilpin; Kjetil Ask; Gerard Cox; Deborah Cook; Jack Gauldie; Peter J Margetts; Laszlo Farkas; Julian Dobranowski; Colm Boylan; Paul M O'Byrne; Robert M Strieter; Martin Kolb Journal: Am J Respir Crit Care Med Date: 2009-01-16 Impact factor: 21.405
Authors: Brent W Kinder; Kevin K Brown; Francis X McCormack; Joachim H Ix; Alma Kervitsky; Marvin I Schwarz; Talmadge E King Journal: Chest Date: 2009-03-02 Impact factor: 9.410
Authors: Harikrishna Tanjore; Xiaochuan C Xu; Vasiliy V Polosukhin; Amber L Degryse; Bo Li; Wei Han; Taylor P Sherrill; David Plieth; Eric G Neilson; Timothy S Blackwell; William E Lawson Journal: Am J Respir Crit Care Med Date: 2009-06-25 Impact factor: 21.405
Authors: Taku Nakashima; Tianju Liu; Hongfeng Yu; Lin Ding; Matthew Ullenbruch; Biao Hu; Zhe Wu; Hideyuki Oguro; Sem H Phan Journal: Am J Respir Crit Care Med Date: 2013-10-15 Impact factor: 21.405
Authors: Vasanthi R Sunil; Kinal N Vayas; Jessica A Cervelli; Elena V Ebramova; Andrew J Gow; Michael Goedken; Rama Malaviya; Jeffrey D Laskin; Debra L Laskin Journal: Toxicol Sci Date: 2018-11-01 Impact factor: 4.849
Authors: Rama Malaviya; Andrew J Gow; Mary Francis; Elena V Abramova; Jeffrey D Laskin; Debra L Laskin Journal: Toxicol Sci Date: 2014-12-30 Impact factor: 4.849
Authors: Rebecca Lee; Charles Reese; Michael Bonner; Elena Tourkina; Zoltan Hajdu; Ellen C Riemer; Richard M Silver; Richard P Visconti; Stanley Hoffman Journal: Am J Physiol Lung Cell Mol Physiol Date: 2014-02-28 Impact factor: 5.464